Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1827-1832, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jialal, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jialal, I.
Related Collections
Right arrow Arnold O. Beckman Conference
Right arrow Proteomics and Protein Markers
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1998;44:1827-1832.)
© 1998 American Association for Clinical Chemistry, Inc.

Proceedings of the 21st Arnold O. Beckman Conference

Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein

Ishwarlal Jialal

Abstract

Cardiovascular disease is the leading cause of morbidity and mortality in Westernized populations. Evolving lipoprotein risk factors include LDL oxidation and lipoprotein(a) [lp(a)]. Several lines of evidence support a role for oxidatively modified LDL in atherogenesis and its in vivo existence. There are both direct and indirect measures of oxidative stress. The most relevant direct measure of lipid peroxidation is urinary F2 isoprostanes. The most common indirect measure of LDL oxidation is quantifying the lag phase of copper-catalyzed LDL oxidation by assaying conjugated diene formation. Lp(a) is increased in patients with cardiovascular and cerebrovascular disease. However, not all prospective studies have confirmed a positive relationship between Lp(a) and cardiovascular events. Lp(a) appears to present three major problems: standardization of the assay, establishing its role in atherogenesis, and the lack of an effective therapy that can substantially lower Lp(a) concentrations. Thus, at the present time, Lp(a) concentrations should not be recommended for the general population but be reserved for patients with coronary artery disease without established risk factors, young patients with coronary artery disease or cerebrovascular disease, or a family history of premature atherosclerosis and family members of an index patient with increased concentrations of Lp(a). Although both LDL oxidation and Lp(a) are evolving risk factors for cardiovascular disease, more data are needed before they become part of the established lipoprotein repertoire.




The following articles in journals at HighWire Press have cited this article:


Home page
 Nicotine Tob ResHome page
R. J. Bloomer and K. Fisher-Wellman
The role of exercise in minimizing postprandial oxidative stress in cigarette smokers
Nicotine Tob Res, January 1, 2009; 11(1): 3 - 11.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
B. Guldiken, S. Guldiken, B. Turgut, N. Turgut, M. Demir, Y. Celik, E. Arikan, and A. Tugrul
The Roles of Oxidized Low-Density Lipoprotein and Interleukin-6 Levels in Acute Atherothrombotic and Lacunar Ischemic Stroke
Angiology, May 1, 2008; 59(2): 224 - 229.
[Abstract] [PDF]

Home page
 Clin. Chem.Home page
S. Devaraj, S. V. Hirany, R. F. Burk, and I. Jialal
Divergence between LDL Oxidative Susceptibility and Urinary F2-Isoprostanes as Measures of Oxidative Stress in Type 2 Diabetes
Clin. Chem., November 1, 2001; 47(11): 1974 - 1979.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S.-E. Bursell and G. L. King
The Potential Use of Glutathionyl Hemoglobin as a Clinical Marker of Oxidative Stress
Clin. Chem., February 1, 2000; 46(2): 145 - 146.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
H. H. Yu, G. S. Ginsburg, M. L. O'Toole, J. D. Otvos, P. S. Douglas, and N. Rifai
Acute Changes in Serum Lipids and Lipoprotein Subclasses in Triathletes as Assessed by Proton Nuclear Magnetic Resonance Spectroscopy
Arterioscler Thromb Vasc Biol, August 1, 1999; 19(8): 1945 - 1949.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.